Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | SmallCapReview.com - Small Cap Stocks To Watch - NVCR, STDY, INFIBy: SmallCapReview.com The two-year survival rate increased from 30 percent to 43 percent for patients treated with Optune together with temozolomide versus patients treated with temozolomide alone. The five-year survival rate increased from five percent to 13 percent for patients treated with Optune together with temozolomide versus patients treated with temozolomide alone. These are the best results reported for newly diagnosed GBM patients in a phase 3 trial to date and represent clinically meaningful increases in landmark survival rates. What They Do: Novocure is an oncology company developing a profoundly different cancer treatment centered on a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. SteadyMed Ltd. (STDY) $5.80. Today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 8,497,393 (the '393 patent) owned by United Therapeutics. In its ruling, the PTAB found all 22 claims in the '393 patent unpatentable and cancelled them, rendering the patent invalid. The IPR was instituted by PTAB in April 2016 after SteadyMed challenged the '393 patent's validity. The '393 patent claims a product made by a process to further purify prostacyclin derivatives, such as treprostinil. Treprostinil is the active pharmaceutical ingredient used in United Therapeutics' Remodulin® and SteadyMed's lead drug candidate, Trevyent, which is in development for the treatment of Pulmonary Arterial Hypertension (PAH). What They Do: SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. Infinity Pharamaceuticals (INFI) $3.22. Today reported updated Phase 1 clinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide- What They Do: Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. About SmallCapReview To register for our free newsletter visit httP://www.smallcapreview.com Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|